|
Research and Markets: Novartis: Performance - Products - Pipeline - Potential - Report Available Now
(M2 PressWIRE Via Acquire Media NewsEdge)
RDATE:03022009
Dublin - Research and Markets
(http://www.researchandmarkets.com/research/b0f53f/novartis_performa)
has announced the addition of the "Novartis: Performance - Products -
Pipeline - Potential" companyprofile to their offering.
Following the merger of Ciba and Sandoz, the spin-off of the
Agribusiness sector and the sale of the remaining activities of the
Industry division, Novartis has become a leading company in the life
sciences field and has operations in approximately 140 countries
worldwide. Novartis is currently organised into the four divisions of
Pharmaceuticals, Consumer Health, Sandoz, and Vaccines & Diagnostics,
created following the acquisition of Chiron Corporation. Within
Pharmaceuticals, the company's current growth drivers include Diovan
(valsartan), Glivec/Gleevec (imatinib), Femara (letrozole) and Zometa
(zoledronate).
Novartis' current pharma growth drivers together account for
approximately 39 per cent of total pharma sales, and we predict that
Diovan and Glivec/Gleevec will continue to demonstrate substantial
sales growth within the medium term. In addition, the recent launch and
approval of a selection of products which include Exjade (deferasirox),
Xolair (omalizumab), Exforge (valsartan+amlodipine) and Lucentis
(ranibizumab), should offset the decline in sales of a number of
Novartis' strategic products. However, this confidence is tempered by
the recent setbacks to the fortunes of Zelnorm/Zelmac (tegaserod),
Prexige (lumiracoxib) and Tekturna (aliskiren). In addition, although
Galvus (vildagliptin) has recently received approved in the EU,
Novartis still faces some hurdles since the approvable letter for
Galvus in the US has allowed Merck's Januvia a head start in this
important market. Similarly, the delay in US approval for the leukaemia
treatment, Tasigna, has left the market open to Bristol-Myers Squibb's
Sprycel. In addition, within the next few years Novartis will be facing
increasing generic competition for many of its current top selling
products such as Zometa (for hypercalcaemia of malignancy and bone
metastases), the blood pressure treatment Lotrel and Famvir, the
antiviral drug for treating herpes, to name but a few.
In the longer term, as a research-intensive company which has benefited
from the Chiron acquisition, Novartis has a strong pharmaceutical
pipeline with a total of 138 compounds under development. With a number
of projects in late-stage development, of particular note is
fingolimod, which is under Phase III development for multiple sclerosis.
This new strategic analysis report Novartis: Pipeline - Products -
Performance - Potential, provides a complete and critical review of the
company and includes unique and independent assessments and forecasts
of key products. These reports are updated with the latest data on a
continuing basis and the full report is released quarterly. Once a year
the report undergoes a major review in line with the company's year
end. Buyers of the print/pdf editions will receive the latest version
and quarterly updated reports for a year. Buyers of the web edition
receive online access for one year via an easy-to-use interface with
fast navigation and a full text search facility. All formats are the
same price.
Executive Summary:
Pharmaceutical company intelligence reports provide a full review of
the company's activities together with five-year sales forecasts for
its key products. The company's financial performance is covered
in-depth, from its latest results to a complete analysis of its latest
full fiscal year and an outlook for the future. A section on company
strategy covers mergers, acquisitions and divestitures, key agreements,
products and R&D. An overview of key products and R&D is followed by a
comprehensive review of the company's product portfolio and research
and development pipeline by therapeutic area. In addition,
supplementary appendices provide more in-depth information on
financials, agreements and corporate events.
Key Topics Covered:
- EXECUTIVE SUMMARY
- THERAPEUTIC AREA FOCUS
- R&D PIPELINE
- CARDIOVASCULAR AND METABOLISM
- ONCOLOGY/HAEMATOLOGY
- NEUROSCIENCE
- OPHTHALMICS/DERMATOLOGY/GASTROINTESTINAL/UROLOGY
- INFECTIOUS DISEASES/TRANSPLANTATION IMMUNOLOGY
- ARTHRITIS/BONE
- RESPIRATORY
- APPENDICES
For more information visit
http://www.researchandmarkets.com/research/b0f53f/novartis_performa
Source: Espicom Business Intelligence Ltd
CONTACT: Laura Wood, Senior Manager, Research and Markets
Fax: +1 646 607 1907 (US)
Fax: +353 1 481 1716 (Rest of World)
e-mail: press@researchandmarkets.com
((M2 Communications Ltd disclaims all liability for information
provided within M2 PressWIRE. Data supplied by named party/parties.
Further information on M2 PressWIRE can be obtained at
http://www.presswire.net on the world wide web. Inquiries to
info@m2.com)).
Copyright ? 2009 M2 Communications Ltd.
[ Back To it.tmcnet.com's Homepage ]
|